Clinical trials: Type 2 Diabetes Mellitus 1
Drug-specific Antibodies, Diabetes Mellitus
Evaluate the Immunogenicity of a Novel Glucagon Formulation
This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards to the potential development of treatment-emergent anti-glucagon antibodies.
- Trial name
- NCT01959334
- Testing
- Nasal Glucagon (NG), Glucagon IM
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1 or 2
Safety and Efficacy of the GlucoMe APP in Patients With Uncontrolled Diabetes Treated With MDI
The study will evaluate the safety and efficacy of computerized GlucoMe App in patients with uncontrolled diabetes treated with MDI.
- Trial name
- NCT03017287
- Testing
- GlucoMe App
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- GlucoMe
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
Type 2 Diabetes Mellitus
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in…
- Trial name
- NCT05731544
- Testing
- BMF-219
- Where
- 39 sites in United States, Canada
- Volunteers
- 443 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
Diabetes Mellitus, Type 2
The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
The aim of this study is to investigate the effects of combined administration of mosapride as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone such as glucagon-like peptide-1 (GLP-1) and…
- Trial name
- NCT02180334
- Testing
- Mosapride citrate, Linagliptin, Acetaminophen (paracetamol)
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Diabetes, Diabetes Mellitus, Type 1
A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®
This trial is conducted in Europe. The aim of this trial is to compare Injections with the Medical Device DV3316 Pen-injector versus FlexPen®.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT02627287
- Testing
- FlexPen®, DV3316 pen-injector
- Where
- 2 sites in Germany
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Surveillance Study of NovoRapid® for New Drug Re-examination
This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01490112
- Testing
- insulin aspart
- Where
- South Korea
- Volunteers
- 1,239 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
Sphingolipids are associated with metabolic diseases. Distribution of plasma sphingolipids in type 1 and type 2 diabetes has never been studied.
- Trial name
- CERADIAB (NCT03447964)
- Testing
- dosing of sphingolipids
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Type 2 Diabetes
Montbretin Clinical Trial in Healthy Volunteers and Type 2 Diabetics
The goal of this clinical trial is to test the investigational product, Montbretin A (MbA) in either individuals with type 2 diabetes (T2D) or healthy participants.
- Trial name
- MbA (NCT05826054)
- Testing
- Montbretin A
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Robert Petrella
Diabete Type 1, Diabete Type 2
VOIES-D-ql - Qualitative Study on Experiences of Diabetes Care Delivery and Planning
Population aging and the increase in incidence and prevalence of potentially disabling chronic conditions make health care more and more complex and costly.
- Trial name
- VOIES-D-ql (NCT04217902)
- Testing
- Description of patients' experiences of diabetes care delivery and planning, Description of health care professionals needs and experiences in diabetes care delivery and planning
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Hospices Civils de Lyon
Type 2 Diabetes Mellitus, Obesity
To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants
XW003 is an acylated human GLP-1 analogue and is being development for diabetes mellitus, obesity and nonalcoholic steatohepatitis (NASH) management.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Nonalcoholic Steatohepatitis
- Trial name
- XW003 (NCT04389775)
- Testing
- Cohort A, Cohort B
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, With Complications
Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus
Diabetic Retinopathy is the leading cause of blindness in the world. Previous studies have documented beneficial effects of physiologic administration of pulsatile insulin on a variety of diabetic complications such as…
- Trial name
- NCT00287651
- Testing
- Pulsatile IV Insulin, Effects of Pulsatile IV Insulin on Diabetic Retinopathy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Florida Atlantic University
Type 1 Diabetes Mellitus
Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus
Primary Objective: To compare the pharmacokinetic (PK) characteristics of single doses of insulin glargine given as U200 and U500 with those of a single dose (SD) of Lantus® U100 in a euglycemic clamp setting in subjects with…
- Trial name
- NCT02201199
- Testing
- insulin glargine U200 HOE901, insulin glargine U500 HOE901, insulin glargine U100 HOE901
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Sanofi
Diabetic Kidney Disease, Chronic Kidney Disease Stage 1
Prospective Decision Impact Trial of KidneyIntelX
The current trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease, Stage 3 (Moderate)
- Trial name
- NCT04960514
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Gastric Pathophysiology in Diabetes
This is a comprehensive pathophysiological study assessing various gastric functions in patients with diabetes mellitus. The investigators aim to examine the stomach with various measurement devices to gain information about its…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Functional Dyspepsia, Gastroparesis
- Trial name
- DiaFLIP (NCT06068114)
- Where
- 5 sites in Czechia, Slovakia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute for Clinical and Experimental Medicine
Diabetic Foot Ulcers
Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers
The purpose of this study is to determine whether AppliGel-G (Gentamicin topical gel) plus oral Ciprofloxacin / Doxycycline are safe and effective in the treatment of mild to moderately infected foot ulcers in diabetic patients.
- Trial name
- NCT02036528
- Testing
- Gentamicin Topical Gel, Ciprofloxacin, Doxycycline
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Royer Biomedical, Inc.
Obesity, Nutritional Deficiency
Comparison of Weight Loss and Nutritional Deficiency After One Anastomosis Gastric Bypass at 150, 170, and 200 cm From the Duodenojejunal Junction
This study is a randomized clinical trial comparing the effects of One Anastomosis Gastric Bypass performed at three different distances from the duodenojejunal junction-150 centimeters, 170 centimeters, and 200 centimeters-on…
- Conditions
- Obesity, Nutritional Deficiency, Type 2 Diabetes Mellitus (T2DM), Bariatric Surgery (Gastric Bypass)
- Trial name
- NCT06664099
- Testing
- One Anastomosis Gastric Bypass (150 cm from Duodenojejunal Junction), One Anastomosis Gastric Bypass (170 cm from Duodenojejunal Junction), One Anastomosis Gastric Bypass (200 cm from Duodenojejunal Junction)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Type 1 Diabetes, Type 2 Diabetes
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
The purpose of this study is to determine whether injecting Symlin and insulin through a multiple injection port is safe and effective.
- Trial name
- NCT00790699
- Testing
- I-PORT, standard injections
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Texas Diabetes & Endocrinology, P.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.